Zidovudine (Azt) Causes An Oxidation of Mitochondrial Dna in Mouse Liver
Open Access
- 1 March 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 29 (3) , 985-987
- https://doi.org/10.1002/hep.510290353
Abstract
Zidovudine (3′–azido–2′,3′–dideoxythymidine [AZT]) inhibits human immunodeficiency virus replication and delays progression of acquired immune deficiency syndrome. We have recently found that, in muscle, AZT causes oxidative damage to mitochondrial DNA (mtDNA) and other signs of mitochondrial oxidative damage. The aim of this work was to test if AZT causes oxidative damage to liver mtDNA. In our study, an experimental mouse model was used in which mice were administered AZT (10 mg/kg body weight/d) in drinking water. Liver mtDNA of mice treated with AZT had 40% more of the oxidized, mutagenic nucleoside, 8–oxo–7,8–dihydroxy–2′deoxyguanosine (8–oxo–dG) than untreated controls. This oxidative damage to mtDNA is caused by a significant increase (of over 240%) in peroxide production by liver mitochondria from AZT–treated mice, which was prevented by dietary administration with vitamins C and E.Keywords
Funding Information
- CICYT/SAF (95/0558)
- (to J.V.) (FIS 98/1462)
- (to F.V.P.) (96/1207)
This publication has 25 references indexed in Scilit:
- AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins.Journal of Clinical Investigation, 1998
- Oxidative Decay of DNAJournal of Biological Chemistry, 1997
- Mitochondrial glutathione oxidation correlates with age‐associated oxidative damage to mitochondrial DNAThe FASEB Journal, 1996
- Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria.Journal of Clinical Investigation, 1992
- Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infectionPathology, 1992
- Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathyThe Lancet, 1991
- Mitochondrial Myopathy Caused by Long-Term Zidovudine TherapyNew England Journal of Medicine, 1990
- Clinical Pharmacology of 3'-Azido-2',3'-Dideoxythymidine (Zidovudine) and Related DideoxynucleosidesNew England Journal of Medicine, 1989
- Zidoyudine-Induced HepatotoxicityAnnals of Internal Medicine, 1989
- Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.Proceedings of the National Academy of Sciences, 1986